Author: Bourin, Michel

Source: Future Neurology, Volume 1, Number 4, July 2006 , pp. 373-388(16)

Publisher: Future Medicine

Abstract:

Aripiprazole has a unique mechanism of action that differs from all currently available antipsychotic agents. Aripiprazole combines potent partial agonist activity at dopamine D₂ receptors and serotonin (5-HT)_1A receptors, with antagonist activity at 5-HT_2A receptors. In short-term clinical studies, aripiprazole produced significant improvements in Positive and Negative Syndrome Scale (PANSS) and Clinical Global Impression (CGI) Scale efficacy scores from baseline compared with placebo. These improvements were similar to those observed with haloperidol and risperidone. Aripiprazole has a rapid onset of efficacy, with improvements in PANSS total and positive subscale scores and CGI severity of illness scores seen as early as 1 week after starting treatment. Aripiprazole's efficacy is maintained in long-term treatment following acute relapse in patients with schizophrenia. In the 52-week maintenance of response study, completion and responder rates were significantly higher with aripiprazole treatment compared with haloperidol, and aripiprazole was superior to haloperidol in treating negative and associated depressive symptoms. Short- and long-term clinical studies show that aripiprazole has a low liability for extrapyramidal side effects and does not increase the risk of weight gain, hyperprolactinemia, QT_cprolongation, somnolence, glucose intolerance or lipid dysregulation. Patients with schizophrenia or schizoaffective disorder can be switched safely and effectively to aripiprazole from their existing antipsychotic medication using any one of three strategies.

Keywords: antipsychotic; aripiprazole; dopamine partial agonist

Document Type: Drug Evaluation

DOI: http://dx.doi.org/10.2217/14796708.1.4.373

Affiliations: 1: EA 3256 Neurobiologie de l'Anxiété et de la Dépression, Faculté de Médecine, 1 rue Gaston Veil, BP 53508, 44035 Nantes Cedex 01, France., Email: michel.bourin@univ-nantes.fr

Publication date: 2006-07-01

More about this publication?

• Future Neurology provides a forum to address the most important challenges and advances in our understanding of neurological disease, and highlights emerging trends and prospects for effective treatments in common but very serious disorders such as stroke, epilepsy, multiple sclerosis and Parkinson's disease.
• Editorial Board
• Information for Authors
• Submit a Paper
• Subscribe to this Title
• Information for Advertisers
• Terms & Conditions
• Information for Librarians
• E-Access Trials
• ingentaconnect is not responsible for the content or availability of external websites

Related content

• In this: publication
• By this: publisher
• In this Subject: Neurology & Psychiatry
• By this author: Bourin, Michel

Website © Publishing Technology. Article copyright remains with the publisher, society or author(s) as specified within the article.

• Terms and conditions
• Privacy policy
• Information for advertisers